A Phase II Trial of Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Cabozantinib (Primary) ; Erlotinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 24 Oct 2017 Status changed from not yet recruiting to recruiting.
- 30 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 1 Nov 2017.
- 14 Jul 2017 New trial record